{
  "ticker": "KRYS",
  "company_name": "Krystal Biotech, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT06724900",
      "title": "A Study Assessing KB304 for the Treatment of Wrinkles in Women",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Wrinkles in Decolletage, Pigmentation, D\u00e9collet\u00e9 Wrinkles",
      "start_date": "2024-11-20",
      "completion_date": "2025-08",
      "enrollment": 0,
      "sponsor": "Krystal Biotech, Inc."
    },
    {
      "nct_id": "NCT07016750",
      "title": "A Study Assessing KB803 Compared to Matching Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa",
      "start_date": "2025-06-20",
      "completion_date": "2026-03",
      "enrollment": 0,
      "sponsor": "Krystal Biotech, Inc."
    },
    {
      "nct_id": "NCT06049082",
      "title": "A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Alpha 1-Antitrypsin Deficiency",
      "start_date": "2024-02-15",
      "completion_date": "2026-12",
      "enrollment": 0,
      "sponsor": "Krystal Biotech, Inc."
    },
    {
      "nct_id": "NCT05095246",
      "title": "A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis",
      "status": "WITHDRAWN",
      "phase": "PHASE1",
      "condition": "Cystic Fibrosis",
      "start_date": "2022-03-08",
      "completion_date": "2024-10-30",
      "enrollment": 0,
      "sponsor": "Krystal Biotech, Inc."
    },
    {
      "nct_id": "NCT04491604",
      "title": "Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa",
      "start_date": "2020-08-17",
      "completion_date": "2022-01-14",
      "enrollment": 0,
      "sponsor": "Krystal Biotech, Inc."
    },
    {
      "nct_id": "NCT04047732",
      "title": "Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)",
      "status": "UNKNOWN",
      "phase": "PHASE1, PHASE2",
      "condition": "TGM-1 Related Autosomal Recessive Congenital Ichthyosis",
      "start_date": "2019-08-27",
      "completion_date": "2025-03",
      "enrollment": 0,
      "sponsor": "Krystal Biotech, Inc."
    },
    {
      "nct_id": "NCT04917874",
      "title": "A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa",
      "start_date": "2021-05-25",
      "completion_date": "2023-07-31",
      "enrollment": 0,
      "sponsor": "Krystal Biotech, Inc."
    },
    {
      "nct_id": "NCT05504837",
      "title": "A Study Assessing KB407 for the Treatment of Cystic Fibrosis",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Cystic Fibrosis",
      "start_date": "2023-06-30",
      "completion_date": "2026-01",
      "enrollment": 0,
      "sponsor": "Krystal Biotech, Inc."
    },
    {
      "nct_id": "NCT06999733",
      "title": "A Study Assessing KB801 for the Treatment of Stage 2 or 3 Neurotrophic Keratitis",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Neurotrophic Keratitis",
      "start_date": "2025-05",
      "completion_date": "2026-10",
      "enrollment": 0,
      "sponsor": "Krystal Biotech, Inc."
    },
    {
      "nct_id": "NCT05970497",
      "title": "A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma",
      "start_date": "2023-10-31",
      "completion_date": "2027-07",
      "enrollment": 0,
      "sponsor": "Krystal Biotech, Inc."
    }
  ],
  "summary": {
    "total_trials": 17,
    "by_phase": {
      "PHASE1, PHASE2": 6,
      "PHASE3": 3,
      "PHASE1": 4,
      "": 3,
      "PHASE2": 1
    },
    "by_status": {
      "ACTIVE_NOT_RECRUITING": 2,
      "RECRUITING": 8,
      "WITHDRAWN": 2,
      "COMPLETED": 3,
      "UNKNOWN": 2
    },
    "active_trials": 10,
    "completed_trials": 3,
    "conditions": [
      "Alpha 1-Antitrypsin Deficiency",
      "Autosomal Recessive Ichthyosis",
      "Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma",
      "Cystic Fibrosis",
      "Dystrophic Epidermolysis Bullosa",
      "Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa",
      "Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa",
      "Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa",
      "Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica Dominans",
      "Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer, Lung Cancer (NSCLC)",
      "Neurotrophic Keratitis",
      "Skin Roughness, Wrinkle, Fine Lines, Skin Thickness",
      "TGM-1 Related Autosomal Recessive Congenital Ichthyosis",
      "Wrinkles in Decolletage, Pigmentation, D\u00e9collet\u00e9 Wrinkles"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:44:24.610393",
    "search_query": "Krystal Biotech, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Krystal+Biotech,+Inc."
  }
}